You are here: Industry Insights > Sprycel

News List

Using Bristol-Myers’ popular leukemia drug to improve anti-PD-1 cancer immunotherapy fiercebiotech
February 22, 2019
Anti-PD-1/L1 therapies, which remove "checkpoints" that prevent the immune system from fighting cancer, have been hailed as a major treatment advance.
FDA approves Bristol-Myers’ Sprycel to treat children with Ph+ ALL pharmaceutical-technology
January 04, 2019
The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s Sprycel (dasatinib) drug for children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL).....
BMS’ Sprycel secures European nod to treat Ph+ CML pharmaceutical-technology
July 12, 2018
Bristol-Myers Squibb (BMS) has secured approval from the European Commission (EC) for the use of its Sprycel (dasatinib) to treat Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML).
FDA Expands Approval of Sprycel americanpharmaceuticacreview
November 13, 2017
As part of its commitment to children and adolescents with cancer, Bristol-Myers Squibb continues to explore pediatric applications for investigational oncology agents within its broad development program.
EPO upholds decision regarding Sprycel cphi-online
February 06, 2017
Bristol-Myers Squibb Company (BMS) has announced that the European Patent Office (EPO) upheld a decision with regard to European Patent No. 1169038, the active ingredient in Sprycel. The EPO upheld a decision that found the patent to be invalid.